Antioxidants and dipyridamole inhibit HIV-1 gp120-induced free radical-based oxidative damage to human monocytoid cells

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue 4, 1997, Pages 223-229

  Foga, Irene O ^a   Nath, Avindra ^b   Hasinoff, Brian B ^a   Geiger, Jonathan D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antioxidants; Dipyridamole; gp120; HIV 1; Iron; Monocytes; Reactive oxygen species; U937 cells

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CATALASE; DEFEROXAMINE; DIPYRIDAMOLE; GLYCOPROTEIN GP 120; IRON; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID PEROXIDATION; MONOCYTE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIOXIDANTS; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; HYPOXANTHINE; MONOCYTES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED; XANTHINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030731799     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199712010-00001     Document Type: Article

References (52)

1. Harrison MJG, McArthur JC. HIV-associated dementia complex. In: Harrison MJG, McArthur JC, eds. AIDS und neurology. New York: Churchill Livingstone, 1995;31-64.
2. - cells. Perspectives in drug discovery and design. B.V. ESCOM Science Publishers, 1996;5:30-42.
3. Glass J, Feder H, Wesselingh LS, McArthur JC. Immunocytochemical quantification of human immunodeficiency virus in the brain. Correlations with dementia. Ann Neurol 1995;38:755-762.
4. Brenneman DE, Westbrook GL, Fitzgerald SP, et al. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988;335:639-42.
5. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA, HIV-1 gp120 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990;248:364-7.
6. Savio T, Levi G. Neurotoxicity of HIV coat protein gp120, NMDA receptors, and protein kinase C: a study with rat cerebellar granule cell cultures. J Neurosci Res 1993;34:265-72.
7. Dawson TM, Dawson VL. gp120 neurotoxicity in primary cortical cultures. Adv Neuroimmunol 1994;4:167-73.
8. 2+], homeostasis and induce neurotoxicity in human embryonic neurons. Eur J Neurosci 1995;7: 2285-93.
9. Brenneman DE, McCune SK, Mervis RF, Hill JM. gp120 as an etiologic agent for NeuroAIDS: neurotoxicity and model systems. Adv Neuroimmunol 1994;4:157-65.
10. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994; 367:188-93.
11. Benos DJ, Hahn BH, Bubien JK, et al. Envelope glycoprotein gp120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: Implications for AIDS dementia complex. Proc Natl Acad Sci USA 1994;91:494-8.
12. 2+, N-methyl-D-aspartate receptors, and AIDS-related neuronal injury. Intern Rev Neurobiol 1994;36:1-27.
13. Nath A, Padua RA, Geiger JD. HIV-1 coat protein gp120-induced increases in levels of intrasynaptosomal calcium. Brain Res 1995; 678:200-6.
14. Epstein LG, Gendelman HE, Lipton SA. Human immunodeficiency virus-1 neuropathogenesis. In: Berger JR, Levy RM, eds. AIDS and the nervous svstem. Philadelphia: Lippincott-Raven Publishers, 1997;59-75.
15. Baruchel S, Wainberg M. The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus. J Leukocyte Biol 1992;52:111-14.
16. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors in intact cells. J Exp Med 1992; 175:1181-94.
17. Sandstrom P, Roberts B, Folks T, Buttke T. HIV gene expression enhances T cell susceptibility to hydrogen peroxide-induced apoptosis. AIDS Res Hum Retroviruses 1993;19:1107-13.
18. Droge W, Eck H, Mihm S. Oxidant-antioxidant status in human immunodeficiency virus infection. Methods Enzymol 1994;233: 594-601.
19. Sappey C, Leclercq P, Coudray C, Faure P, Micoud M, Favier A. Vitamin, trace element and peroxide status in HIV seropositive patients: asymptomatic patients present a severe β-carotene deficiency. Clinica Chim Acta 1994;230:35-42.
20. Sonnerborg A, Carlin G, Akerlund B, Jarstrand C. Increased production of malondialdehyde in patients with HIV infection. Scand J Infect Dis 1989;20:287-90.
21. Edeas M, Khalfoun Y, Lazizi, et al. Effect of the liposolubility of free radical scavengers on the production of antigen p24 from a HIV infected monocytic cell line. Soc Biol Fil 1995;189:367-73.
22. Pietraforte D, Tritarelli E, Testa U, Minetti M. gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages. J Leukocyte Biol 1994;55:175-82.
23. Shatrov VA, Ratter F, Gruber A, Droge W, Lehmann V. HIV type 1 glycoprotein 120 amplifies tumor necrosis factor-induced NF-κB activation in Jurkat cells. AIDS Res. Hum Retroviruses 1996;12: 1209-16.
24. Braughler JM, Duncan LA, Chase RL. Interaction of lipid peroxidation and calcium in the pathogenesis of neuronal injury. Central Nervous System Trauma 1985;2:269-83.
25. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine, 2nd ed. Oxford: Clarendon Press, 1989.
26. Balsinde J, Mollinedo F. Induction of the oxidative reponse and of concanavalin A-binding capacity in maturing U937 cells. Biochim Biophys Acta 1990;1052:90-5.
27. Gotz ME, Kunig G, Riederer P, Youdim MBH. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994;63:37-122.
28. Guillard O, Sonnet J, Lauwerys R. Reactive oxygen species production in whole blood from AIDS patients. Clin Chim Acta 1989; 185:113-14.
29. Greenspan HC. The role of reactive oxygen species, antioxidants and phytopharmaceuticals in human immunodeficiency virus activity. Med Hypoth 1992;40:85-92.
30. Schwarz KB. Oxidative stress during viral infection: a review. Free Rad Biol Med 1996;21:641-9.
31. Fuchs J, Ochsendorf F, Schofer H, Milbradt R, Rubsamen-Waigmann H. Oxidative imbalance in HIV infected patients. Med Hypoth 1991;36:60-4.
32. Dreyer EB, Lipton SA. The coat protein gp120 of HIV-1 inhibits astrocyte uptake of excitatory amino acids via macrophage arachidonic acid. Eur J Neurosci 1995;7:2502-7.
33. 2+], responses not only in type-2 but also type-1 astrocytes and oligodendrocytes of the rat cerebellum. Eur Neurosci Assoc 1995;7:1333-41.
34. Muller WEG, Schoder HC, Ushijima H, Dapper J, Bormann J. gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Eur J Pharmacol 1992;226:209-14.
35. Bennett BA, Rusyniak DE, Hollingsworth K. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res 1995;705:168-76.
36. Aggoun-Zouaoui D, Charriaut-Marlangue C, Rivera S, Jorquera I, Ben-Ari Y, Represa A. The HIV-1 envelope protein gp120 induces neuronal apoptosis in hippocampal slices. NeuroReport 1996;7: 433-6.
37. Diop AG, Dussartre C, Barthe D, Hugon J. Neuroprotective properties of calretinin against the HIV-1 gp120 toxicity. Neurosci Res Commun 1996;18:107-14.
38. Meucci O, Miller RJ. gp120-induced neurotoxicity in hippocampal pyramidal neuron cultures: protective action of TGF-β1. J Neurosci 1996;16:4080-8.
39. Peterhans E. Chemiluminescence: an early event in the interaction of sendai and influenza viruses with mouse spleen cells. Virol 1980;105:445-55.
40. Mills EL, Debets-Ossenkopp Y, Verbrugh HA, Verhoef J. Initiation of the respiratory burst of human neutrophils by influenza virus. Infect Immunol 1981;32:1200-05.
41. Lobner D, Choi D. Dipyridamole increases oxygen-glucose deprivation-induced injury in cortical cell culture. Stroke 1994;25: 2085-9.
42. de la Cruz J, Garcia P, Sanchez de la Cuesta F. Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals. Thrombosis Res 1992;66:277-85.
43. Geiger JD, Parkinson, FE, Kowaluk EA. Regulators of endogenous adenosine levels as therapeutic agents. In: Jacobson KA, Jarvis MF, eds. Purinergic approaches in experimental therapeutics New York: Wiley-Liss, 1997.
44. Morisaki N, Slitts J, Bartels-Tonei L, Milio G, Panaganamala R, Cornwell D. Dipyridamole: an antioxidant that promotes the proliferation of aorta smooth muscle cells. Artery 1982;11:88-107.
45. Iuliano L, Violi F, Ghiselli A, Alessandri C, Balsano F. Dipyridamole inhibits lipid peroxidation and scavenges oxygen radicals. Lipids 1989;24:430-3.
46. de la Cruz J, Sintas A, Moreno A, Garcia-Campos Sanchez de la Cuesta F. Dipyridamole and RA-642 inhibit the production of superoxide and free radical damage to rat lens. Pharmacol Toxicol 1991;69:201-4.
47. Iuliano L, Pratica D, Ghiselli A, Bonavita M, Violi F. Reaction of dipyridamole with the hydroxyl radical. Lipids 1992;27:349-53.
48. Iuliano L, Pedersen J, Rotilio G, Ferro D, Violi F. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Rad Biol Med 1995;18:239-47.
49. Szebeni J. An old drug in a new role: dipyridamole in the treatment of HIV-1 infections? Orv Hetill 1991;132:1907-12.
50. Szebeni J, Wahl S, Popovic M, et al. Dipyridamole potentiates the inhibition by 3′-azido-3′-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc Natl Acad Sci USA 1989;86: 3842-6.
51. Betageri G, Szebeni J, Hung K, et al. Effect of dipyridamole on transport and phosphorylation of thymidine and 3′-azido-3′-deoxythymidine in human monocyte/macrophages. Biochem Pharmacol 1990;40:867-70.
52. Weinstein J, Bunow B, Weislow O, et al. Synergistic drug combination therapy: dipyridamole/3′-azido-3′-deoxythymidine in particular and principles of analysis in general. Ann N Y Acad Sci 1990;616:367-85.